

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Expert Committee on Biological Standardization

Thirty-eighth Report

World Health Organization
Technical Report Series
771



World Health Organization, Geneva 1988

ISBN 92 4 120771 X

© World Health Organization 1988

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or *in toto*, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

ISSN 0512-3054

PRINTED IN SWITZERLAND

88/7618 - Schüler SA - 6200

CONTENTS

	Page
General	
Freedom of international reference materials from contamination by hepatitis B virus and human immunodeficiency viruses	9
Possible adverse effect of secondary desiccation on the stability of lyophilized international reference materials	9
Assignment of units of activity to reference materials	10
Distribution of international reference materials by the four International Laboratories for Biological Standards	11
Reference materials for uses other than biological standardization	11
Definition of "production area" for biologicals	12
The residual content of animal serum or its constituents in vaccines prepared in cell cultures or grown in media containing animal serum	13
Meeting of the WHO Consultative Group on Poliomyelitis Vaccines	13
Thromboplastins	14
Interferons	15
Selection of candidate suppliers of BCG vaccines to UNICEF	17
Future meetings	17
SUBSTANCES	
Antibiotics	
1. Teicoplanin	17
Antibodies	
2. Cytomegalovirus immunoglobulin	18
3. Tetanus immunoglobulin	18
4. Varicella zoster immunoglobulin	19
5. Anti-toxoplasma IgM serum	19
6. Anti-rabies serum, equine, and rabies immunoglobulin	20
Allergens	
7. Alternaria (<i>Alternaria alternata</i>) extract and Bermuda grass (<i>Cynodon dactylon</i>) pollen extract	20
8. Dog (<i>Canis domesticus</i>) hair and dander extract	21
9. Purified protein derivatives (PPD) of tuberculin	21
Antigens	
10. Measles vaccine (live)	22
11. Rabies vaccine	22
Blood products	
12. Anti-D (anti-Rh ₀) complete blood-typing serum (chemically modified)	23
13. Human protein C	23
	3

14. Human blood coagulation factors II, IX, and X in concentrates.....	23
15. Human tissue plasminogen activator (t-PA).....	24
16. Haemoglobin F.....	24
17. Haemoglobin A ₂	25
18. Haemoglobin variants	25

Endocrinological and related substances

19. Islet cell antibodies	25
20. Thyroid stimulating antibodies	26
21. Corticotrophin (ACTH), human	26
22. Erythropoietin	26
23. Human growth hormone.....	27
24. Inhibin	27
25. Human interleukin-2	28
26. Human pituitary luteinizing hormone.....	28
27. Human atrial natriuretic factor.....	28
28. Renin	29
29. Somatomedin C.....	29

Miscellaneous

30. Vitamin B ₁₂ in serum.....	29
31. Interferon, human, fibroblast, β	29
32. Interferon, human, recombinant, $\alpha_1(\alpha D)$	30
33. Interferon, human, recombinant, $\alpha_2(\alpha_{2b})$	30
34. Interferon, human, recombinant, β_{ser17}	30
35. Interferon, murine, α	31
36. Interferon, murine, β	31
37. Interferon, murine, γ	31
38. Digitalis	32

REQUIREMENTS FOR BIOLOGICAL SUBSTANCES

39. Requirements for poliomyelitis vaccine (oral) (addendum 1987).....	32
40. Requirements for measles vaccine (live) (revised 1987)	32
41. Requirements for Japanese encephalitis vaccine (inactivated) for human use	32
42. Requirements for human interferons made by recombinant DNA techniques	33
43. Requirements for the production of human interferons prepared from lymphoblastoid cells	33
44. Requirements for hepatitis B vaccine prepared from plasma (revised 1987)	34
45. Requirements for hepatitis B vaccines made by recombinant DNA techniques	34
46. Requirements for stability of yellow fever vaccines (addendum 1987).....	34
47. List of yellow fever vaccine manufacturers approved by WHO (revised 1987).....	35
48. Requirements for antimicrobial susceptibility tests	
1. Agar diffusion tests using antimicrobial susceptibility discs (addendum 1987)	35

49. Requirements for dried BCG vaccine (amendment 1987).....	35
50. Draft requirements for oral poliomyelitis vaccine prepared in continuous cell lines	36

ANNEXES

Annex 1. Standardization of interferons: report of a WHO Informal Consultation	37
Annex 2. Modification for lyophilized BCG vaccines of the procedure for evaluating the acceptability in principle of vaccines proposed to United Nations agencies for use in immunization programmes	88
Annex 3. Model certificate for the release of BCG vaccines acquired by United Nations agencies.....	90
Annex 4. Requirements for poliomyelitis vaccine (oral) (addendum 1987)....	91
Annex 5. Requirements for measles vaccine (live) (revised 1987)	93
Annex 6. Requirements for Japanese encephalitis vaccine (inactivated) for human use	133
Annex 7. Requirements for human interferons made by recombinant DNA techniques	158
Annex 8. Requirements for hepatitis B vaccine prepared from plasma (revised 1987)	181
Annex 9. Requirements for yellow fever vaccine (addendum 1987).....	208
Annex 10. Laboratories approved by WHO for the production of yellow fever vaccine	210
Annex 11. Requirements for antimicrobial susceptibility tests 1. Agar diffusion tests using antimicrobial susceptibility discs (addendum 1987).....	211
Annex 12. Requirements for dried BCG vaccine (amendment 1987).....	212
Annex 13. Biological substances: international standards and reference reagents.....	213
Annex 14. Requirements for biological substances and other sets of recommendations.....	216

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Geneva, 1-9 December 1987

Members

- Dr T. Bektimirov, Director, Tarasevič State Institute for the Standardization and Control of Medical Biological Preparations, USSR Ministry of Health, Moscow, USSR (*Chairman*)
- Dr J. Furesz, Director, Bureau of Biologics, Drugs Directorate, Tunney's Pasture, Ottawa, Ontario, Canada
- Dr C. Guthrie, Operations Director, Commonwealth Serum Laboratories, Parkville, Victoria, Australia (*Rapporteur*)
- Dr M.C. Hardegree, Director, Division of Bacterial Products, Office of Biologics Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
- Dr H. Mirchamsy, Associate Director, Razi State Institute of Sera and Vaccines, Teheran, Islamic Republic of Iran (*Vice-Chairman*)
- Dr M.S. Nasution, Director, Perusahaan Negara "Bio Farma", Bandung, Indonesia
- Dr R. Netter, Director-General, National Health Laboratory, Paris, France
- Dr S.N. Saxena, Director, Central Research Institute, Kasauli, India
- Professor G. Swaniker, Department of Basic Medical Sciences, Faculty of Medicine, University of Papua New Guinea, Boroko, Papua New Guinea
- Dr Xiang Jian-zhi, Chairman, Expert Committee on Science and Technology, Shanghai Institute of Biological Products, Shanghai, China

Representative(s) of other organizations

International Union of Immunological Societies

- Dr H. Baer, Laboratory of Allergenic Products, Office of Biologics, Food and Drug Administration, Bethesda, MD, USA

Secretariat

- Dr M. Arita, Department of Enteroviruses, National Institute of Health, Tokyo, Japan (*Temporary Adviser*)
- Dr D.H. Calam, Chemistry Division, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)
- Dr M. Gheorghiu, Chief, BCG Laboratory, Pasteur Institute, Paris, France (*Temporary Adviser*)
- Professor S.E. Grossberg, Chairman, Department of Microbiology, Medical College of Wisconsin, Milwaukee, WI, USA (*Temporary Adviser*)
- Professor W. Hennessen, Berne, Switzerland (*Temporary Adviser*)
- Dr S.L. Jeffcoate, Department of Endocrinology, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)
- Dr H. Krijnen, Director, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands (*Temporary Adviser*)
- Dr A. Lee, Biological Products and Standards Department, Central Veterinary Laboratory, New Haw, Weybridge, Surrey, England (*Temporary Adviser*)

Dr S.M. Lewis, Royal Postgraduate Medical School, London, England
(*Temporary Adviser*)
Mr J. Lyng, Head, Laboratory for Biological Standardization, State Serum
Institute, Copenhagen, Denmark (*Temporary Adviser*)
Dr D. Magrath, National Institute for Biological Standards and Control, Potters
Bar, Herts., England (*Temporary Adviser*)
Dr P. Sizaret, Acting Chief, Biologicals, WHO, Geneva, Switzerland (*Secretary*)
Dr W.W. Wright, Senior Scientist, Drug Standards Division, United States
Pharmacopeia, Rockville, MD, USA (*Temporary Adviser*)
Dr D. Zewdie, National Research Institute of Health, Addis Ababa, Ethiopia
(*Temporary Adviser*)

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30772

